Retevmo (selpercatinib)

pCPA File Number: 21931

Negotiation Status:

Concluded with an LOI

Indication(s):

monotherapy treatment of rearranged during transfection (RET) fusion-positive differentiated thyroid carcinoma (DTC) in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib

Sponsor/Manufacturer:

Eli Lilly Canada Inc.

CADTH Project Number:

PC0274

pCPA Engagement Letter Issued:

2022-11-17

Negotiation Process Concluded:

2023-03-31